Opportunities and challenges in the development of experimental drug combinations for cancer

Rachel W. Humphrey, Laura M. Brockway-Lunardi, David T. Bonk, Kathleen M. Dohoney, James H. Doroshow, Sandra J. Meech, Mark J. Ratain, Suzanne L. Topalian, Drew M. Pardoll

Research output: Contribution to journalReview article

Abstract

It is becoming increasingly evident that cancers are dependent on a number of altered molecular pathways and can develop diverse mechanisms of resistance to therapy with single agents. Therefore, combination regimens may provide the best hope for effective therapies with durable effects. Despite preclinical data to support this notion, there are many challenges to the development of targeted combinations including scientific, economic, legal, and regulatory barriers. A discussion of these challenges and identification of models and best practices are presented with intent of aiding the research community in addressing real and perceived barriers to the development of combination therapies for cancer.

Original languageEnglish (US)
Pages (from-to)1222-1226
Number of pages5
JournalJournal of the National Cancer Institute
Volume103
Issue number16
DOIs
StatePublished - Aug 17 2011

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Humphrey, R. W., Brockway-Lunardi, L. M., Bonk, D. T., Dohoney, K. M., Doroshow, J. H., Meech, S. J., Ratain, M. J., Topalian, S. L., & Pardoll, D. M. (2011). Opportunities and challenges in the development of experimental drug combinations for cancer. Journal of the National Cancer Institute, 103(16), 1222-1226. https://doi.org/10.1093/jnci/djr246